A Study to Better Understand the Biological and Molecular Mechanisms Involved in Glioblastoma Recurrence and Progression

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

45 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-09-30

Study Completion Date

2030-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

BORDEAUX-GLIO is a prospective, monocentric study which will describe the molecular, immune and metabolic pathways involved in the progression and relapse of glioblastoma, using blood and tumor samples from patients who have undergone surgery for newly diagnosed or recurrent glioblastoma in the center.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Metabolic, Transcriptomic and Proteomic Characteristics in Relapsed Glioblastoma

NCT06430424

Relapsed Cancer Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype

RECRUITING

Study of Tissue Samples From Patients With Glioma or Other Brain Tumors

NCT00967200

Central Nervous System Lymphoma

COMPLETED

Biomarker-based Algorithm for Diagnosis of Glioma

NCT04194593

Glioma

UNKNOWN

Stem Cell Analysis, Omics (Including Immunomics) and Artificial Intelligence in Glioblastoma

NCT05941234

Glioblastoma, IDH-wildtype

RECRUITING NA

Multicentre Validation of How Vascular Biomarkers From Tumor Can Predict the Survival of the Patient With Glioblastoma

NCT03439332

Glioblastoma

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Glioblastoma is the most common and aggressive primary brain tumor in adults, whose relapse is almost systematic despite surgery, radiation therapy and temozolomide (STUPP protocol). Several clinical trials evaluating targeted therapy and immune checkpoint inhibitors have led to disappointed results. There is an unmet need to better understand the molecular and immune mechanisms underlying the invasion and progression of these tumors, in order to identify new therapeutic targets. The Bordeaux University Hospital is a leading French treatment center for glioblastoma, providing a large number of biological samples that can be analyzed at the molecular, immune and metabolic levels by specialized local teams.

Tumor tissue will be collected during patient surgery from primitive or recurrent glioblastoma, as well as blood samples, to perform transcriptomic and metabolomic analysis, including spatial transcriptomic and metabolomic, ex vivo generation of γδT lymphocytes and patient-derived xenografts.

A secondary objective is to develop, in preclinical models, innovative drugs with radiosensitizing effect and a γδT cell immunotherapy active against glioblastoma.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glioblastoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Recruited patient

Glioblastoma patient with indication for neurosurgery

samples

Intervention Type OTHER

A 50 ml blood sample will be taken from the patient before the operation, and two 0.3 cm3 tumor samples will be taken during the operation from the resected tumor.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

samples

A 50 ml blood sample will be taken from the patient before the operation, and two 0.3 cm3 tumor samples will be taken during the operation from the resected tumor.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients of 18 years or older, with highly suspected glioblastoma on neuro-imagery
* Planned surgical tumor resection,
* No objection to participate in research
* Signed genetic consent

Exclusion Criteria

* Patients under guardianship, curatorship or protective supervision
* Taking immunosuppressants
* Pregnant or breast-feeding women
* Patients deprived of their liberty by judicial or administrative decision, or under psychiatric care

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No